Glykos (Finland)

Glykos (Finland) is a Helsinki-based biotechnology company active in two related areas of oncology and biopharmaceutical research: the development of next-generation antibody-drug conjugates (ADCs) and the provision of specialized glycan analysis services through its Glykos Analytics unit. The company describes itself as striving to develop best-in-class ADCs against hematologic and solid tumor targets, with the goal of widening the therapeutic window of these targeted cancer medicines so that patients can receive higher, more effective doses while avoiding off-target toxicities. Glykos' ADC platform is built around proprietary hydrophilic linker technology and cytotoxic drug derivatives. The company states that its auristatin-class payload MMAU has shown better efficacy and higher tolerability than VC-MMAE (vedotin) technology. Its technology is designed to allow site-specific conjugation of practically any monoclonal antibody with a client's payload of choice, producing homogeneous and effective next-generation ADCs. The company has developed cytotoxic drug derivatives across three payload classes: auristatin, anthracyclin, and exatecan. Glykos positions itself as open to collaboration and co-development with pharmaceutical partners and antibody developers. In parallel, Glykos Analytics provides high-throughput analytical services to characterize glycans of proteins as well as other biomolecules, cells, and tissues. These services include rapid mass spectrometric glycan profiling and full structural analysis of glycans. The company uses mass spectrometry, microanalytical chromatography, glycan and protein microarrays, and NMR spectroscopy. Glykos states that it has applied its glycomics technology to stem cells and was the first to characterize and publish the glycome of several human stem cell types, and that it has mapped glycan profiles of major cancer types and cancer stem cells, identifying novel biomarkers and treatment targets. It works with some of the world's largest pharmaceutical companies and leading research institutions. Glykos is headquartered in Helsinki, Finland. It is a private company and does not appear to be listed on a public stock exchange. Its dual focus on ADC therapeutics and glycomics services places it at the intersection of oncology drug development and biopharmaceutical analytics.

Glykos (Finland) is a Helsinki-based biotechnology company. Public evidence about its corporate history is limited, but its official website and Wikidata entry establish it as a company in Helsinki, Finland, active in antibody-drug conjugate (ADC) development and glycan analysis services. The company's work spans two connected areas. On the therapeutics side, Glykos has developed an in-house ADC technology platform. According to the company, this platform uses proprietary hydrophilic linker technology and cytotoxic drug derivatives designed to overcome several limitations of current ADC applications. The company states that its auristatin-class payload MMAU has shown better efficacy and higher tolerability than VC-MMAE (vedotin) technology. Glykos reports that its technology enables site-specific conjugation of practically any monoclonal antibody with a client's payload of choice, producing homogeneous and effective next-generation ADCs. It has developed cytotoxic drug derivatives in three payload classes: auristatin, anthracyclin, and exatecan. The company describes its pipeline as focused on oncology, with ADC asset development against hematologic and solid tumor targets. On the analytics side, Glykos Analytics provides high-throughput analytical services to characterize glycans of proteins as well as other biomolecules, cells, and tissues. These services include rapid mass spectrometric glycan profiling and full structural analysis of glycans. The company uses advanced high-precision, high-throughput techniques such as mass spectrometry, microanalytical chromatography, glycan and protein microarrays, and NMR spectroscopy. Glykos states that it has applied its glycomics technology to stem cells and was the first to characterize and publish the glycome of several human stem cell types. It also reports having mapped glycan profiles of major cancer types and cancer stem cells and identified novel biomarkers and treatment targets. The company works with some of the world's largest pharmaceutical companies and leading research institutions on projects ranging from structural characterization of difficult-to-analyze glycoproteins to large high-throughput process development projects. Glykos is headquartered in Helsinki, Finland. It is a private company and does not appear to be listed on a public stock exchange. The company welcomes collaboration and co-development opportunities with pharmaceutical partners and antibody developers.

Developer of best-in-class ADCs with a widened therapeutic window, and provider of high-throughput glycan analysis services to pharmaceutical and research partners.

• ADC technology platform

  In-house developed next-generation antibody-drug conjugate platform using proprietary hydrophilic linker technology and cytotoxic drug derivatives.

• MMAU payload

  Auristatin-class cytotoxic payload reported to show better efficacy and higher tolerability over VC-MMAE (vedotin) technology.

• Glykos Analytics glycan profiling

  High-throughput analytical services for glycan characterization of proteins, biomolecules, cells, and tissues, including mass spectrometric profiling and full structural analysis.

1. 1Glykos official websiteglykos.fi
2. 2Services | Glykosglykos.fi
3. 3Glykos (Finland) - Wikidatawikidata.org